All News

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

WHO experts weighed decades of high-quality studies against flawed analyses, finding consistent evidence that current vaccines pose no autism-related risk.

Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.

Your daily dose of the clinical news you may have missed.

Clevenger speaks to primary care clinicians, emphasizing 3 priorities: engage family as partners, ask about agitation, and recognize its danger to patient and caregiver.

Intranasal epinephrine emerges as a safe, effective alternative for anaphylaxis treatment, offering ease of use and promising real-world results.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

Genetic predisposition to psoriasis appears to raise depression risk, offering insights into shared inflammatory mechanisms and implications for screening.

A cohort study of 531 851 primary care patients found routine AUDIT-C alcohol screening scores predict 8-year all-cause mortality, with strongest effects in younger adults.

The inquiry follows internal requests for closer review of trial findings and real-world evidence; regulators have not yet indicated any planned actions.